<unk>  is used to treat acute iron poisoning, especially in small children. This agent is also frequently used to treat hemochromatosis, a disease of iron accumulation that can be either genetic or acquired. Acquired hemochromatosis is common in patients with certain types of chronic anemia (e.g. thalassemia and myelodysplastic syndrome) who require many blood transfusions, which can greatly increase the amount of iron in the body. Treatment with iron-chelating drugs such as<unk>  reduces mortality in persons with sickle cell disease or β‐thalassemia who are transfusion dependent. Administration for chronic conditions is generally accomplished by subcutaneous injection over a period of 8–12 hours each day. Administration of<unk>  after acute intoxication may color the urine a pinkish red, a phenomenon termed "vin rosé urine". Apart from iron toxicity,<unk>  can be used to treat aluminium toxicity (an excess of aluminium in the body) in select patients. In US, the drug is not FDA-approved for this use.<unk>  is also used to minimize doxorubicin's cardiotoxic side effects and in the treatment of a patient with aceruloplasminemia.<unk>  maybe effective for improving neurologic outcomes in persons with intracranial hemorrhage, although the evidence supporting the efficacy and safety for this indication was weak. Some published manuscripts suggesting the use of<unk>  for patients diagnosed with COVID-19 because of the high level of ferritin among them.
Deferoxamine
Dimercaprol
Mercapturic acid
Sodium thiosulfate 
Disufenton sodium
Dimercaptosuccinic acid
Alphos
Fomepizole